Company intelligence / Profile preview
National Vaccine and Serum Institute
- Ownership
- Private
- Employees
- ~7000
- Development stage
- Commercial
Overview
The company has multiple commercialized vaccines used globally in national immunization programs. Its products are WHO-prequalified and distributed to over 170 countries. Recent clinical results include positive EMA opinion for a novel TB diagnostic aid and successful launch of malaria vaccine R21/Matrix-M™ with University of Oxford[1][3][5].
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccineMonoclonal antibodyRecombinant proteinAntiseraBiologic
- Industry
- Pharma
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on National Vaccine and Serum Institute.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on National Vaccine and Serum Institute.